Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair.

Rasmussen ST, Ilyas AM

Journal of orthopaedics7 Aug 2025Cited by 2 (Europe PMC)

PMID40895356DOI10.1016/j.jor.2025.08.016PepBankPUB-40895356

Publisher page PubMedAsk about this study

Summary

ObjectivesThe use of glucagon-like peptide-1 (GLP-1) receptor agonists is increasingly common among orthopaedic patients, often prescribed for type 2 diabetes mellitus and obesity, which are frequent comorbidities. Recent studies have explored the effects of GLP-1's on postoperative outcomes in orthopaedic procedures. This study evaluates the impact of GLP-1 on re-operation risk following rotator cuff repair (RCR).MethodsA retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network. Patients with documented RCR and no prior GLP-1 use were included in the control group. Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group. After comparing baseline characteristics, cohorts were matched based on selected covariates. Outcomes were compared using risk ratios (RR) with 95 % confidence intervals (CI). A subgroup analysis by GLP-1 indication (type 2 diabetes or weight loss) was performed.ResultsPropensity score matching yielded well-balanced cohorts of 5306 patients. Subgroup analysis included 781 patients per group. At 3, 6, and 12 months post-RCR, the control group showed no difference in reoperation risk. In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).ConclusionThe use of GLP-1 was not associated with a higher reoperation risk after RCR, suggesting that these medications can safely be taken leading up to RCR. However, increased short-term risks in diabetes patients highlight the need for individualized care and further study of GLP-1 effects on orthopaedic outcomes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
After rotator cuff repair, pooled GLP-1 use for diabetes was linked to higher adhesive capsulitis risk than use for obesity.
In plain wordsAfter shoulder repair, pooled GLP-1 use for diabetes was linked to more frozen shoulder than use for obesity.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAdhesive capsulitis at 3 months
Study
n = 1,562
Comparator
GLP-1 use for obesity
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk ratio of adhesive capsulitis at 3 months
2.2
GLP-1 for diabetes versus obesity, P = 0.0321
95% CI of risk ratio
1.05 to 4.62
GLP-1 for diabetes versus obesity
Source sentences
Summary
In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network.
Summary · context
Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4089535601
02HumanNot a test of Liraglutide aloneObservational studySafety outcome
After rotator cuff repair, pooled GLP-1 use for diabetes was linked to higher adhesive capsulitis risk than use for obesity.
In plain wordsAfter shoulder repair, pooled GLP-1 use for diabetes was linked to more frozen shoulder than use for obesity.
Peptide
Liraglutide
Outcome
IncreaseAdhesive capsulitis at 3 months
Study
n = 1,562
Comparator
GLP-1 use for obesity
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk ratio of adhesive capsulitis at 3 months
2.2
GLP-1 for diabetes versus obesity, P = 0.0321
95% CI of risk ratio
1.05 to 4.62
GLP-1 for diabetes versus obesity
Source sentences
Summary
In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network.
Summary · context
Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-4089535602
03HumanNot a test of Semaglutide aloneObservational studySafety outcome
After rotator cuff repair, pooled GLP-1 use for diabetes was linked to higher adhesive capsulitis risk than use for obesity.
In plain wordsAfter shoulder repair, pooled GLP-1 use for diabetes was linked to more frozen shoulder than use for obesity.
Peptide
Semaglutide
Outcome
IncreaseAdhesive capsulitis at 3 months
Study
n = 1,562
Comparator
GLP-1 use for obesity
Outcome group
Bone and joint · Musculoskeletal
Measurements
Risk ratio of adhesive capsulitis at 3 months
2.2
GLP-1 for diabetes versus obesity, P = 0.0321
95% CI of risk ratio
1.05 to 4.62
GLP-1 for diabetes versus obesity
Source sentences
Summary
In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).
2 context sentences(design, population, supporting numbers)
Summary · context
A retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network.
Summary · context
Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Show in the study text Report a problemFND-4089535603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

PepBank is a research reference. Talk to a doctor before you use any peptide.